Due to their simple and low-cost manufacturing process, matrix tablets are pharmaceutical dosage forms most widely used for the formulation of oral controlled release of drugs (1). These systems involve dispersion of one or more drugs in a support structure, which in the majority of the cases is of polymeric nature.
EXPERIMENTAL

Materials
The following materials were used for the preparation of matrix tablets: Ethocel™ 7 FP (particle size range 5-15 mm), Ethocel™ 10 FP (particle size range 3-15 mm), Ethocel™ 100 FP (particle size range 30-60 mm) (Colorcon Ltd.,UK) as matrix forming polymers, verapamil hydrochloride (mean particle size 120.5 ± 45.2 mm) (Recordatti, Italy), carbamazepine (mean particle size 138.9 ± 47.8 mm) (Fagron, Spain) and sodium diclofenac (mean particle size 212.4 ± 75.9 mm) (Fagron, Spain) as model drugs with different solubility. Solubility values as well as the true density of the drugs were taken from the literature: verapamile (45.4 g L -1 and 1.160 g cm -3 ); carbamazepine (0.12 g L -1 and 1.330 g cm -3 ) and sodium diclofenac (20.4 g L -1 and 1.022 g cm -3 ).
Fast Flo lactose (Foremost, USA) and microcrystalline cellulose (MCC) (AVICEL PH 102), (FMC BioPolymer, Ireland) were used as fillers while magnesium stearate (Fagron, Spain) and colloidal silicon dioxide (AEROSIL 200) (Degussa, Germany) were employed as lubricants and flow aid, respectively.
Tablet preparation
Twenty batches of inert matrices containing 90 mg of verapamil hydrochloride, carbamazepine or diclofenac and an initial porosity between 0 and 5 % were prepared. Table I shows the composition of the studied formulations. Ten more batches containing 90 mg of carbamazepine and 40 % (m/m) of ethylcellulose (5 batches of Ethocel TM 7 FP and 5 batches of Ethocel TM 10 FP) were prepared with 5 different porosities, ranging from 0 to 25 % (V/V). Table I shows the composition of these formulations as well.
All materials, with the exception of magnesium stearate, were blended for 10 minutes in a Turbula mixer (Willy A. Bachofen, Switzerland). Magnesium stearate was added and blended for an additional 2 minutes. A standard eccentric tablet machine (Bonals A-300, Spain) equipped with 9 mm flat punches was used to compress the mixtures in order to obtain tablets with a target weight of 300 mg.
The powder blends were weighed and placed manually into the die of the compression machine (60 tablets per lot). The position of the upper punch was adjusted according to the initial porosity and crushing force of the tablets.
Tablet characterization
The mass of 10 tablets corresponding to each lot was measured using an electronic balance (Sartorius CP 2245). Thickness and diameter of 10 tablets of each lot were measured using a 25-mm digital micrometer (Comecta, SA).
The volume of 10 tablets from each batch was calculated according to the following Eq. (1):
where V is the tablet volume. H and D are tablet thickness and diameter, respectively. The initial porosity (e 0 ) was determined using known volume and weight values according to the following Eq. (2):
where V real is the volume of the tablet and V theor is the theoretical volume of the tablet, determined as the sum of volumes of individual components (obtained dividing the mass of each component by its real density). Friability was determined for 20 tablets per lot using a friability tester Erweka TA (Germany) according to USP 26 (21) .
Crushing forces of the tablets were determined using 10 tablets per lot, with a crushing strength tester Sotax HT1 (Sotax, Switzerland).
Drug release
Dissolution studies were performed using the paddle method in a USP dissolution apparatus Sotax AT7 smart (Sotax) for 6 tablets from each batch. 900 mL of distilled water at 37 ± 0.5°C was used as dissolution medium. The stirring speed was fixed at 50 rpm for verapamil hydrochloride and sodium diclofenac and at 100 rpm for carbamazepine. Samples of 5 mL were withdrawn at 0.25, 0.5, 1.0, 1.5, 2, 3, 6 and 8 h. The percentage of drug released was measured using a UV/VIS spectrophotometer Agilent 8453 (USA) at 276 nm for sodium diclofenac, 278 nm for verapamil hydrochloride and 284 nm for carbamazepine.
Drug release data obtained for extended release matrices were fitted into the following equations: Eq. (3) (zero-order model), Eq. (4) proposed by Higuchi (22) , Eq. (5) proposed by Korsmeyer et al. (23) and Eq. (6) proposed by Peppas and Sahlin (24) .
where Q is the quantity of drug released at time t, k 0 is the zero order release rate constant in equation 3, b is the Higuchi release rate constant in equation 4, k k is the Korsmeyer kinetic constant in equation 5, t is the release time, n is the Korsmeyer time exponent that depends on the release mechanism and on the shape of the matrix tested (25) , k d and k r are the diffusion and relaxation rate constants, respectively, and m is the purely Fickian diffusion exponent for a device of any geometrical shape exhibiting controlled release.
Optimum values for the parameters included in each equation were determined by linear or nonlinear least-squares fitting methods using the SPSS 14.0 software. The determination coefficient (R 2 ) was used to test the applicability of release models.
Results of the dissolution studies were employed to estimate the percolation threshold of the different components of the formulations. Phase transition is related to the presence of the percolation threshold of one component of the formulation, and normally produces a significant change in release profiles (11, 26) .
RESULTS AND DISCUSSION
Tablet characterization
Results on the tablet diameter and thickness were used to determine the apparent volume of tablets. The weight and density of the different components of tablets were employed to calculate the volume fractions corresponding to each component and the initial porosity of the tablets manufactured. As an example, Table II shows the results (including the crushing strength and tablet friability data) for batches FP C1 to FP C5 (containing carbamazepine and Ethocel TM 7 FP). As it can be seen, high hardness values were obtained. These values are considered adequate for obtaining controlled release systems, especially inert matrix systems that must not erode during the drug release process. On the other hand, friability values are adequate, with the exception of batch FP C1, containing only 10 % of ethylcellulose. This fact seems to indicate that the plasticity of ethylcellulose improves the cohesion strength of the tablet.
Drug release profiles and release kinetics
Thirty batches of tablets were prepared employing three different drugs, two different fillers, a lubricant mixture and three different viscosity grades of Ethocel TM . Table I shows the composition and porosity level of each formulation. Results of dissolution studies are discussed below.
Estimation of the ethylcellulose percolation threshold
Release profiles as well as kinetic parameters of the different batches were employed to estimate the excipient percolation threshold of each formulation. A sudden change in kinetic parameters indicates a change in the release behaviour that could be indicative of a phase transition due to the presence of the percolation threshold of ethylcellulose.
Considering the release profiles of the different batches, the percolation threshold of the matrix forming polymer can be situated between 20 and 30 % (m/m) for the matrices containing sodium diclofenac (batches FP D, Fig. 1b ). Changes in kinetic parameters shown in Table III and Table III) is also consistent with this assumption. On the other hand, in the matrices prepared with Ethocel TM 7 FP and verapamil hydrochloride (Fig. 2a) , no clear change in release profiles can be observed.
In the case of inert matrices containing carbamazepine and Ethocel TM 7 FP (batches FP C), the lot FP C3 (30 % (m/m) of Ethocel TM 7 FP) shows an anomalous behaviour (Fig. 1a) . Therefore, the change in release behaviour attributable to the percolation of the polymer is observed between 20 and 40 % (m/m) of Ethocel TM 7 FP. The results of kinetic studies confirm this statement, since a fast increase in kinetic constants can be observed when the concentration of ethylcellulose is lower than 40 % (m/m), indicating lower control of drug release. These data support the results previously discussed in this section.
Therefore, as a general behaviour, these results suggest that the volumetric fraction of Ethocel, needed to obtain a percolating cluster of this polymer controlling the drug release, ranges from 21.7 (lot FP D2) to 31.8 % (V/V) (lot FP V8). This fact means that matrices containing less than 21.7 % (V/V) Ethocel are expected to contain isolated clusters of this polymer, which will result in their lower ability to control drug release as well as higher probability of tablet disintegration during the drug release process.
Effect of drug substances. Percolation of drug substances
Although drug load was kept constant in weight, its volume fraction was not the same for the different drugs and batches, due to different densities of the substances employed as well as to the differences in volume of the tablets obtained.
Sodium diclofenac
Matrices containing sodium diclofenac showed the highest drug volume fraction, ranging from 33.5 to 37.5 % (V/V) of drug. Addition of the initial porosity of the matrices to the drug volume fraction leads to a total porosity range from 35.1 to 39.5 % (V/V).
This could explain why sodium diclofenac matrices show the fastest drug release rate, despite lower water solubility of sodium diclofenac compared to the solubility of verapamil hydrochloride (20.4 vs. 45.4 g L -1 ) (Figs. 1a,b and 2a) .
Another argument that could explain faster release from sodium diclofenac matrices is the fact that diclofenac molecules have smaller volume than verapamil molecules, so that higher diffusivity could be expected. 
Verapamil hydrochloride
The drug volume fraction for verapamil hydrochloride matrices ranges between 30.3 and 34.3 % (V/V). The total porosity, calculated adding the initial porosity of the matrices to the volumetric fraction of the drug, ranges from 33.1 to 38.1 % (V/V).
Therefore, it can be expected that both sodium diclofenac and verapamil hydrochloride are situated above or very close to their percolation thresholds in the studied matrices (17) . The obtained drug release profiles seem to confirm this hypothesis. Some of the batches released 100 % of drug during the release assay and even for the lots containing higher amounts of polymer, the release rate shows significant values, suggesting that the drug was not encapsulated by the polymer.
Carbamazepine
In matrices containing drugs with slow dissolution kinetics, the presence of a fast dissolution filler will mask the percolation threshold of the drug. Therefore, due to the low dissolution rate of carbamazepine and to the presence of lactose, as soluble filler in these matrices, the release profiles do not seem to be strongly affected by the percolation threshold of carbamazepine. Fig. 1a shows a clear change in the release behaviour of lot FP C3 and lot FP C4. The volume fraction of the filler is 33.2 for lot FP C3 and 23.9 % (V/V) for FP C4 (Table II) . Therefore, this change can be attributed to the percolation of the filler in carbamazepine matrices. This means that the batches containing up to 23.9 % (V/V) lactose (40 and 50 % (m/m) of Ethocel) do not contain a percolating cluster of lactose, which is isolated by other components of the formulation, resulting in a slower release rate.
Batches with a content of lactose of 33.2 % (V/V) or higher (10 to 30 % (m/m) of Ethocel) contain a percolating cluster of lactose, i.e., in these tablets the soluble filler is dissolved as water ingresses into the matrix, acting as a channel former within the inert matrix through which the drug is released. In this way, the soluble filler exerts a strong influence on matrix properties, resulting in faster drug release (see lots FP C1, FP C2 and FP C3 in Fig. 1a) .
Nevertheless, as it can also be observed in Fig. 1a , there is an unexpected behaviour of lot FP C3, showing a very fast initial drug release. This burst effect is clearly stronger than that exhibited by lots FP C1 and FP C2, though these lots contain a higher amount of lactose. As it can be observed in Table II, Therefore, the three main components of this matrix: the poorly soluble drug, the insoluble polymer and the freely water soluble filler are above or very close to 30 % (V/V). This is a special situation, which will allow all of these three components to percolate through the tablet. This structure, which can be called a tricoherent system, could be the reason for the anomalous behaviour found in the release assay of lot FP C3.
Effect of polymer particle size and viscosity
In order to study the effect of the polymer particle size and viscosity grade, matrix tablets containing verapamil hydrochloride, MCC and two polymers with different viscosity grades (Ethocel TM 7 FP and Ethocel TM 100 FP) were prepared. These polymers have different particle sizes, Ethocel TM 7 FP: 5-15 mm, and Ethocel TM 100 FP: 30-60 mm as well as different viscosity grades (7 and 100 mPa s, respectively).
These two factors are expected to have opposite influence on drug release: on one hand, according to the percolation theory, a substance with a smaller particle size can spread over the system in a more effective way, exerting stronger influence on the system properties (27) (28) (29) . In this sense, the matrices containing finer particles of ethylcellulose (Ethocel TM 7 FP) are expected to show slower drug release.
On the other hand, the higher viscosity of Ethocel TM 100 FP would be expected to reduce the drug release rate, if release was through the polymer itself. Figs. 2a and 2b show that the smaller particle size of the polymer exerted a stronger effect on the drug release rate than polymer viscosity, showing the matrices containing Ethocel TM 100 FP had a slightly faster release rate. This fact may be related to the compressibility of polymers, where lower viscosity grades undergo plastic deformation to a larger extent, thus leading to lower porosity.
Effect of tablet porosity
Five batches containing 30 % of carbamazepine and 40 % of Ethocel TM 7 FP as well as 5 batches containing 30 % of carbamazepine and 40 % of Ethocel TM 10 FP were prepared with 5 different porosity levels ranging from 0 to 25 %. Table I shows the composition and porosity levels of these batches.
Regardless of the type of polymer employed, it can be observed (Fig. 3) that the tablets with lower initial porosity (0-5 % (V/V) batches CA) clearly show slower drug release. Changes in kinetic parameters are shown in Table IV . This could be attributed to the fact that these matrices are below the percolation threshold of the soluble filler plus the initial porosity. The volumetric fraction of lactose for batch 7FP CA is 23.9 % and the initial porosity is 0-5 %. Batch 10 FP CA has a volumetric fraction of lactose of 23.8 % (V/V) and the initial porosity is also 0-5 % (V/V). The volumetric fraction of the soluble filler and initial porosity is in both cases lower than 30 % and therefore below the percolation threshold, which is expected to be between 30-35 % (V/V).
On the other hand, lots prepared with more than 15 % (V/V) of initial porosity (Batches CD and CE) are expected to be above the percolation threshold of the filler plus initial porosity, showing a higher release rate.
Batches with an intermediate initial porosity compressed between 5-15 % (V/V) (lots CB and CC) are expected to be very close to the percolation threshold of the filler plus initial porosity. These batches show a behaviour intermediate between the previously depicted patterns.
The effect of porosity plus soluble filler was studied in the previous paragraph. Nevertheless, the effect of porosity can be also studied as an individual factor. It is well known from the percolation theory that, assuming a random distribution, the percolation of pores through a solid system shows a percolation threshold around 16 % (28). Fig. 4 shows the behaviour of the percent of drug released at 1 h, 3 h and 6 h as a function of the initial tablet porosity.
As this figure shows, the obtained data are in good agreement with this hypothesis, showing an increase in the drug released for tablets containing more than 16 % of initial porosity.
CONCLUSIONS
It has been shown in this paper that the release behaviour of the multicomponent inert matrices prepared can be explained according to the percolation ranges of their com- ponents. Studies of these percolation ranges are important in order to develop more robust controlled release formulations employing ethylcellulose as a matrix forming polymer. Concentration of the matrix forming polymer must be above its percolation threshold to guarantee the integrity of the matrix and to modulate drug release. Furthermore, the role of filler solubility and its percolation has been shown to be important factors affecting the release behaviour of the drug from inert matrices. For these reasons, application of the percolation theory to the manufacturing of multicomponent inert matrices enables a science-based formulation that will lead to the concept of quality by design.
